"Loss of Heterozygosity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
Concept/Terms
Loss of Heterozygosity- Loss of Heterozygosity
- Heterozygosity Loss
- Allelic Loss
- Allelic Losses
- Heterozygosity, Loss of
Below are MeSH descriptors whose meaning is more general than "Loss of Heterozygosity".
Below are MeSH descriptors whose meaning is more specific than "Loss of Heterozygosity".
This graph shows the total number of publications written about "Loss of Heterozygosity" by people in Harvard Catalyst Profiles by year, and whether "Loss of Heterozygosity" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 2 | 2 | 4 |
| 1998 | 8 | 16 | 24 |
| 1999 | 9 | 12 | 21 |
| 2000 | 5 | 16 | 21 |
| 2001 | 9 | 20 | 29 |
| 2002 | 8 | 13 | 21 |
| 2003 | 4 | 11 | 15 |
| 2004 | 10 | 19 | 29 |
| 2005 | 9 | 12 | 21 |
| 2006 | 4 | 16 | 20 |
| 2007 | 6 | 15 | 21 |
| 2008 | 3 | 10 | 13 |
| 2009 | 6 | 13 | 19 |
| 2010 | 6 | 9 | 15 |
| 2011 | 7 | 12 | 19 |
| 2012 | 4 | 5 | 9 |
| 2013 | 4 | 11 | 15 |
| 2014 | 2 | 9 | 11 |
| 2015 | 4 | 5 | 9 |
| 2016 | 3 | 11 | 14 |
| 2017 | 2 | 11 | 13 |
| 2018 | 0 | 11 | 11 |
| 2019 | 3 | 5 | 8 |
| 2020 | 4 | 6 | 10 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 7 | 8 |
| 2023 | 0 | 2 | 2 |
Below are the most recent publications written about "Loss of Heterozygosity" by people in Profiles.
-
Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30643.
-
Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity. J Natl Compr Canc Netw. 2023 07; 21(7):688-693.e3.
-
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma. Ann Oncol. 2023 03; 34(3):275-288.
-
Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone. Cancer Cell. 2022 Nov 14; 40(11):1276-1278.
-
Bi-allelic loss-of-function variants in TMEM147 cause moderate to profound intellectual disability with facial dysmorphism and pseudo-Pelger-Huët anomaly. Am J Hum Genet. 2022 Oct 06; 109(10):1909-1922.
-
Upper motor neuron signs and early onset gait abnormalities in young children with bi-allelic VWA1 variants. Am J Med Genet A. 2022 Dec; 188(12):3531-3534.
-
Bi-allelic loss-of-function variants in PPFIBP1 cause a neurodevelopmental disorder with microcephaly, epilepsy, and periventricular calcifications. Am J Hum Genet. 2022 08 04; 109(8):1421-1435.
-
Genome plasticity driven by aneuploidy and loss of heterozygosity in Trypanosoma cruzi. Microb Genom. 2022 06; 8(6).
-
Frequent somatic gene conversion as a mechanism for loss of heterozygosity in tumor suppressor genes. Genome Res. 2022 06; 32(6):1017-1025.
-
A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo. Sci Transl Med. 2022 03 02; 14(634):eabm0306.